Literature DB >> 14216147

THE DIAGNOSIS OF LEUKEMIA BY TISSUE CULTURE.

A ENGLISH.   

Abstract

A shallow glass slide chamber technique has been used for the short-term tissue culture of peripheral leukocytes and marrow. Seventy-three normal persons and 105 patients with various hematologic disorders were studied. Characteristic culture patterns were observed in normal individuals and in patients with leukemia. The technique was found to be of value for distinguishing leukemia from conditions which mimic it and for defining the malignant nature of some of the myeloproliferative disorders. On the basis of repeated studies in 22 patients with leukemia while under treatment, the peripheral leukocyte tissue culture technique was not found to be a sensitive enough guide for the control of therapy.

Entities:  

Keywords:  LEUKEMIA; LEUKOCYTES; NEOPLASM DIAGNOSIS; PHOTOMICROGRAPHY; TISSUE CULTURE

Mesh:

Year:  1965        PMID: 14216147      PMCID: PMC1927888     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  5 in total

1.  Myeloblastic leukemia preceded by prolonged hematologic disorder.

Authors:  M J WILLIAMS
Journal:  Blood       Date:  1955-05       Impact factor: 22.113

2.  Periodic-acid-Schiff positivity in erythroblasts with special reference to Di Guglielmo's disease.

Authors:  D QUAGLINO; F G HAYHOE
Journal:  Br J Haematol       Date:  1960-01       Impact factor: 6.998

3.  Preleukemic acute human leukemia.

Authors:  M BLOCK; L O JACOBSON; W F BETHARD
Journal:  J Am Med Assoc       Date:  1953-07-11

4.  Biochemical studies in chronic myelocytic leukemia, polycythemia vera and other idiopathic myeloproliferative disorders.

Authors:  W N VALENTINE; W S BECK; J H FOLLETTE; H MILLS; J S LAWRENCE
Journal:  Blood       Date:  1952-10       Impact factor: 22.113

5.  Incorporation of 32P and adenine 14C into DNA by human bone marrow cells in vitro.

Authors:  L G LAJTHA; R OLIVER; F ELLIS
Journal:  Br J Cancer       Date:  1954-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.